
Sanofi SNY
€ 39.24
-1.57%
Geschäftsbericht 2025
hinzugefügt 18.04.2026
Sanofi Betriebszyklus 2011-2026 | SNY
Betriebszyklus Jährlich Sanofi
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 330 | 311 | 314 | 308 | 307 | 286 |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 330 | 286 | 309 |
Betriebszyklus anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebszyklus | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Amphastar Pharmaceuticals
AMPH
|
237 | $ 21.75 | 1.59 % | $ 1.02 B | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
4.89 | $ 0.91 | 1.61 % | $ 6.69 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
332 | $ 22.29 | 1.5 % | $ 3.69 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | ||
|
Aquestive Therapeutics
AQST
|
223 | $ 4.1 | 0.37 % | $ 438 M | ||
|
Arcutis Biotherapeutics
ARQT
|
291 | $ 23.2 | -0.26 % | $ 2.95 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
129 | $ 1.42 | -1.39 % | $ 378 M | ||
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | ||
|
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
127 | - | - | $ 546 M | ||
|
Cardiff Oncology
CRDF
|
294 | $ 1.72 | -0.29 % | $ 115 M | ||
|
BioXcel Therapeutics
BTAI
|
1.66 K | $ 1.07 | 0.94 % | $ 13.1 M | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | ||
|
Esperion Therapeutics
ESPR
|
99.7 | $ 1.95 | 1.83 % | $ 405 M | ||
|
CASI Pharmaceuticals
CASI
|
135 | - | - | $ 35.4 M |